Recent Updates
Recently added Catalysts
COLL

Collegium to Present at the Deutsche Bank Health Care Conference

Key Takeaway: CANTON, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 12:50 p.m. ET at the Intercontinental Hotel Boston. About

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+28%
120-day peak, hindsight
Typical move
0.4%
average across 3 past catalysts
Lead asset
DFN-15 Active
Phase 3 · Migraine Headache

Full Press Release Details

CANTON, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 12:50 p.m. ET at the Intercontinental Hotel Boston.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Last updated: May 2, 2018